Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Wells Fargo & Company MN

Wells Fargo & Company MN lifted its holdings in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 69.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 215,538 shares of the company's stock after acquiring an additional 88,209 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Altimmune worth $1,554,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Virtu Financial LLC purchased a new position in shares of Altimmune during the 3rd quarter valued at about $674,000. Barclays PLC raised its position in Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company's stock worth $956,000 after acquiring an additional 75,064 shares during the period. Geode Capital Management LLC lifted its stake in Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company's stock valued at $10,244,000 after buying an additional 74,194 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of Altimmune by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company's stock valued at $1,482,000 after acquiring an additional 31,482 shares in the last quarter. Finally, Kraematon Investment Advisors Inc. purchased a new stake in shares of Altimmune during the fourth quarter worth $222,000. Institutional investors and hedge funds own 78.05% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on ALT. Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price target for the company. William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Finally, HC Wainwright reissued a "buy" rating and set a $12.00 price target on shares of Altimmune in a research report on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $20.83.

Insider Activity at Altimmune

In other news, CFO Gregory L. Weaver acquired 10,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were bought at an average cost of $5.20 per share, with a total value of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares of the company's stock, valued at $52,000. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 4.10% of the stock is currently owned by insiders.

Altimmune Price Performance

Shares of NASDAQ ALT traded up $0.64 during midday trading on Friday, hitting $5.81. 849,088 shares of the company's stock were exchanged, compared to its average volume of 2,838,599. The firm's fifty day simple moving average is $5.16 and its 200-day simple moving average is $6.66. The company has a market cap of $447.07 million, a PE ratio of -3.73 and a beta of 0.91. Altimmune, Inc. has a twelve month low of $3.55 and a twelve month high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. Equities analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.